Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CASR | P41180 | 9/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | VNN1 | O95497 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6009449 | 0.89 | CASR (0.44) | HPGDCASRADRB1GHSRDPP4 | |
| SCHEMBL5503937 | 0.78 | HPGD (0.36) | HPGDNPC1RAB9ASMN1; SMN2CASR | |
| SCHEMBL5504082 | 0.74 | CASR (0.39) | HPGDNPC1RAB9ASMN1; SMN2CASR | |
| SCHEMBL5504957 | 0.73 | — | — | |
| SCHEMBL5506849 | 0.69 | GHSR (0.39) | HPGDNPC1RAB9ASMN1; SMN2CASR | |
| SCHEMBL354792 | 0.69 | HPGD (0.38) | HPGDNPC1RAB9ASMN1; SMN2CASR | |
| SCHEMBL6009959 | 0.69 | KEAP1 (0.36) | SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL5503668 | 0.69 | CASR (0.39) | HPGDNPC1RAB9ASMN1; SMN2CASR | |
| SCHEMBL6009423 | 0.67 | DPP4 (0.44) | HPGDSMN1; SMN2CASRADRB1L3MBTL1 | |
| SCHEMBL5500333 | 0.66 | HPGD (0.35) | HPGDNPC1RAB9ASMN1; SMN2GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | APP, PSEN1, TTR | HPGD 1617/4885NPC1 37/4885RAB9A 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.